future of glp-1 drugs Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 GLP-1s: The Future of Preventive

Description

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model

Lancet 2021;397:97184.ArticlePubMed 48

As 2024 drew to a close, Englands NICE finalised its guidance for Mounjaro, recommending its use in the primary care setting, for treating adults with a body mass index (BMI) 35 kg/m2 and at least one weight-related co-morbidity, alongside a reduced-calorie diet and increased exercise, with no restriction on treatment duration, equating to a total eligible population of 3.4 million patients [5]

& Brabant, G

For weight loss that may have stalled on tirzepatide, the resources about plateaus on GLP-1 therapy provide useful framing that applies regardless of which specific compound is involved